Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma.
生物技術(shù)公司Zealand Pharma首席執(zhí)行官表示,在由諾和諾德(Novo Nordisk)和禮來(Eli Lilly)主導(dǎo)的快速增長的肥胖癥市場,其他制藥商仍有可能“贏得”競爭。
您已閱讀5%(282字),剩余95%(5129字)包含更多重要信息,訂閱以繼續(xù)探索完整內(nèi)容,并享受更多專屬服務(wù)。